非小细胞肺癌患者的新选择—厄洛替尼（特罗凯）

目的：综述了厄洛替尼的靶向作用、药动学、临床研究及不良反应皮疹与疗效的关系。方法：通过查阅国内外文献总结了厄洛替尼的单药试验及合并用药试验，并对研究结果进行分析。结果：单药试验表明厄洛替尼能够显著延长患者的生存期并提高生存质量：合并用药试验未发现显著性优势。其不良反应皮疹的发生及程度与患者的生存期及疾病缓解率存在显著性关系。结论：厄洛替尼能够显著延长晚期或转移型非小细胞肺癌患者的生存期，其不良反应皮疹与疗效的相关性仍需进一步研究。

Erlotinib(Tarceva):a new option for patients with non-small-cell lung cancer

Objective: To review the targeted effect,pharmacokinetics,clinical studies of erlotinib and the relationship be-tween efficacy and rash caused by erlotinib. Methods: Studying and analyzing single drug and combined trials of erlotinib by litera-ture retrieval. Results: Single drug trials show that erlotinib can prolong survival significantly and improve the quality of life,while no difference was found when combined with other drugs. Patients who experience much more severe rash have a significantly longer survival. Conclusion: Erlotinib can significantly prolong survival of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC). The relationship between efficacy and rash needs further studies.